Keyphrases
Clinical Trials
100%
Drug Development
100%
Risk Outcomes
100%
Patient Outcomes
100%
Patient Benefit
100%
Risk-benefit
100%
Patient Risk
100%
Olaparib
100%
Ovarian Cancer
25%
Objective Response Rate
25%
Drug Manufacturer
25%
New Indication
25%
Oncology
12%
Data Extraction
12%
Response Rate
12%
Complete Response
12%
PubMed
12%
Adverse Events
12%
MEDLINE
12%
Embase
12%
Solid Tumors
12%
Duplication
12%
Cochrane
12%
Overall Survival
12%
Progression-free Survival
12%
Drug Efficacy
12%
Trial Characteristics
12%
Oncologic
12%
Cancer Clinical Trials
12%
Cumulative Risk
12%
Adult Participants
12%
Repurposing
12%
Solid Cancer
12%
Adverse Event Rates
12%
Median Progression-free Survival
12%
Novel Chemotherapy
12%
Safety Criteria
12%
Therapy Options
12%
Mutation Characteristics
12%
Pooled Analysis
12%
Time Investment
12%
Capital Investment
12%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Drug Development
100%
Olaparib
100%
Malignant Neoplasm
37%
Adverse Event
25%
Progression Free Survival
25%
Ovary Cancer
25%
Pharmaceutical Manufacturing
25%
Chemotherapy
12%
Overall Survival
12%
Solid Malignant Neoplasm
12%
Medicine and Dentistry
Clinical Trial
100%
Olaparib
100%
Malignant Neoplasm
37%
Adverse Event
25%
Progression Free Survival
25%
Ovarian Cancer
25%
Lifespan
12%
Drug Therapy
12%
Clinician
12%
Solid Malignant Neoplasm
12%
Oncology
12%
Overall Survival
12%
Drug Efficacy
12%
Pooled Analysis
12%
Chemotherapy
12%